HYDERABAD, May 8: Natco Pharma Wednesday announced
that its marketing partner Alvogen has received the final
approval of Abbreviated New Drug Application (ANDA) from the
US Food and Drug Administration (FDA) for Nitroglycerin
Sublingual Tablets USP, 0.3 mg, 0.4 mg, and 0.6 mg.
Nitroglycerin sublingual tablets are used to treat
episodes of angina (chest pain) in people who have coronary
artery disease (narrowing of the blood vessels that supply
blood to the heart).
Pfizer Pharmaceuticals Ltd markets this drug under its
brand Nitrostat Sublingual Tablets in the same strengths
mentioned above.
Quoting market reports Natco said Nitroglycerin
Sublingual Tablets had total annual sales of around USD 77.3
million in the US market, for the year ending 2018. (PTI)
&&&
Follow our WhatsApp channel